NCT03330561 2024-04-22
PRS-343 in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
Clinical Trials
5 trialsNCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT03953833 2023-09-14
B003-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT03281824 2022-01-18
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients
Alteogen, Inc.
Phase 1 Completed
NCT02135159 2017-08-14
BIRTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Completed